Being critical to tumour invasion pathways, ANXA2 association with distinct CRC subtypes places it as an important player in CRC progression, a useful tool for screening patients with CRC and a possible target for new drugs aimed to interfere with the EMT. The gene discussed is ANXA2; the disease is colorectal carcinoma.